1.

Inhibition of Smooth Muscle β-Catenin Hinders Neointima Formation After Vascular Injury.

Riascos-Bernal DF, Chinnasamy P, Gross JN, Almonte V, Egaña-Gorroño L, Parikh D, Jayakumar S, Guo L, Sibinga NES.

Arterioscler Thromb Vasc Biol. 2017 May;37(5):879-888. doi: 10.1161/ATVBAHA.116.308643. Epub 2017 Mar 16.

PMID:
28302627
2.

Utility of Systematic Isolation of immune cell subsets from HIV-infected individuals for miRNA profiling.

Bargalló ME, Guardo AC, Maleno MJ, Miralles L, Egaña-Gorroño L, Escribà T, García F, Gatell JM, Arnedo M, Plana M.

J Immunol Methods. 2017 Mar;442:12-19. doi: 10.1016/j.jim.2016.12.005. Epub 2016 Dec 27.

PMID:
28039100
3.

MicroRNA Profile in CD8+ T-Lymphocytes from HIV-Infected Individuals: Relationship with Antiviral Immune Response and Disease Progression.

Egaña-Gorroño L, Guardo AC, Bargalló ME, Planet E, Vilaplana E, Escribà T, Pérez I, Gatell JM, García F, Arnedo M, Plana M M; HIV Controllers Consortium of the AIDS Spanish Network.

PLoS One. 2016 May 12;11(5):e0155245. doi: 10.1371/journal.pone.0155245. eCollection 2016.

4.

Differential microRNA expression profile between stimulated PBMCs from HIV-1 infected elite controllers and viremic progressors.

Egaña-Gorroño L, Escribà T, Boulanger N, Guardo AC, León A, Bargalló ME, Garcia F, Gatell JM, Plana M, Arnedo M; HIV Controllers Consortium of the AIDS Spanish Network.

PLoS One. 2014 Sep 16;9(9):e106360. doi: 10.1371/journal.pone.0106360. eCollection 2014.

5.

Contribution of genetic background and antiretroviral therapy to body fat changes in antiretroviral-naive HIV-infected adults.

Egaña-Gorroño L, Martínez E, Pérez I, Escribà T, Domingo P, Gatell JM, Arnedo M.

J Antimicrob Chemother. 2014 Nov;69(11):3076-84. doi: 10.1093/jac/dku266. Epub 2014 Jul 15.

PMID:
25185137
6.

Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients.

Egaña-Gorroño L, Martínez E, Domingo P, Loncà M, Escribà T, Fontdevila J, Vidal F, Negredo E, Gatell JM, Arnedo M.

Antimicrob Agents Chemother. 2014 Nov;58(11):6717-23. doi: 10.1128/AAC.03481-14. Epub 2014 Aug 25.

7.

Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.

Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van 't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albini L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez E, Arnedo M, Egaña-Gorroño L, Gatell JM, Law M, Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, De Wit S, Berger F, Mauss S, de Paz Sierra M, Losso M, Belloso WH, Leyes M, Campins A, Mondi A, De Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negredo E, Gutierrez M, Domingo P, Fischer J, Fätkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC, Fellay J, Telenti A, Tarr PE; MAGNIFICENT Consortium; INSIGHT; Swiss HIV Cohort Study.

Clin Infect Dis. 2013 Jul;57(1):112-21. doi: 10.1093/cid/cit196. Epub 2013 Mar 26.

8.

Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy.

Egaña-Gorroño L, Martínez E, Cormand B, Escribà T, Gatell J, Arnedo M.

AIDS. 2013 Feb 20;27(4):529-38. doi: 10.1097/QAD.0b013e32835d0da1.

PMID:
23262498
9.

Association study of lipoprotein(a) genetic markers, traditional risk factors, and coronary heart disease in HIV-1-infected patients.

Egaña-Gorroño L, Martínez E, Escribà T, Calvo M, Gatell JM, Arnedo M.

Front Immunol. 2012 Dec 6;3:367. doi: 10.3389/fimmu.2012.00367. eCollection 2012.

Supplemental Content

Loading ...
Support Center